Apellis drops as disappointing Syfovre sales drive Q3 miss
Apellis Pharmaceuticals (APLS) stock falls as company's Q3 2024 financials disappoint with lower-than-expected U.S. sales ...
Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results
Generated $196.8 million in 3Q 2024 revenues, including $176.6 million in U.S. net product salesGrew SYFOVRE® (pegcetacoplan injection) demand by ...
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Call Transcript November 5, 2024 Apellis Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.46 EPS, expectations were $-0.32. Operator: Good morning, ladies ...
Yahoo Finance8d
Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results
Generated $152.0 million in SYFOVRE U.S. net product revenue in the third quarter 2024. SYFOVRE commercial vials grew by approximately 7% quarter-over-quarter. SYFOVRE net selling price declined ...
Apellis' Q3 Loss Wider Than Expected, Syfovre Drives Revenues Y/Y
Apellis Pharmaceuticals, Inc. APLS incurred third-quarter 2024 loss of 46 cents per share, wider than the Zacks Consensus Estimate of a loss of 32 cents. The company had incurred a loss of $1.17 per ...
Yahoo Finance8d
Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results
Generated $152.0 million in SYFOVRE U.S. net product revenue in the third quarter 2024. SYFOVRE commercial vials grew by approximately 7% quarter-over-quarter. SYFOVRE net selling price declined ...